Dr. Flynn on CDK Inhibitors for the Treatment of CLL

Joseph M. Flynn, DO
Published: Monday, Apr 07, 2014

Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).

Most CDK inhibitors have been looked at in both solid and liquid tumors, Flynn says. CDK inhibitors have been looked at in CLL because it is preferable to treat the disease with an agent that has a low toxicity profile​.

CDK inhibitors have an interesting history in CLL. Alvocidib (flavopiridol) was looked at first, but did not demonstrate much activity. Nevertheless, alvocidib opened the door for other CDK inhibitors in this disease, like dinaciclib.
 

<<< View more from the 2014 AACR Annual Meeting

Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).

Most CDK inhibitors have been looked at in both solid and liquid tumors, Flynn says. CDK inhibitors have been looked at in CLL because it is preferable to treat the disease with an agent that has a low toxicity profile​.

CDK inhibitors have an interesting history in CLL. Alvocidib (flavopiridol) was looked at first, but did not demonstrate much activity. Nevertheless, alvocidib opened the door for other CDK inhibitors in this disease, like dinaciclib.
 

<<< View more from the 2014 AACR Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x